Management of Rising INR (3.2→3.9) on Held Warfarin
Continue holding warfarin and recheck INR in 1-2 days, then resume at a reduced weekly dose once INR trends back toward therapeutic range.
Immediate Action
Your INR has risen from 3.2 to 3.9 despite holding one dose, indicating continued anticoagulant effect from warfarin's long half-life. Continue holding warfarin for now 1.
The 2012 CHEST guidelines specifically address this scenario: for patients with a single out-of-range INR of 0.5 above therapeutic (your case: 3.9 vs target of 2.0-3.0), continue withholding the current dose and retest within 1-2 weeks 1. However, given your INR is rising rather than falling, more frequent monitoring is warranted.
Monitoring Schedule
Recheck INR in 1-2 days (not 1-2 weeks, given the upward trend) 1, 2. The anticoagulant effect of warfarin persists beyond 24 hours 3, so you need to confirm the INR is trending downward before restarting.
What to Expect:
- If INR is falling (e.g., 3.0-3.5): Continue holding and recheck in another 1-2 days
- If INR reaches 2.5-3.0: Resume warfarin at a reduced weekly dose (decrease by 5-20% of your previous weekly total) 4
- If INR continues rising or exceeds 4.5: Consider low-dose oral vitamin K (2.5 mg) 5, 4
Rationale for This Approach
The 2018 ASH guidelines note that for an INR of 3.3 in a patient with generally stable control, a recall interval of 2-4 weeks might be reasonable after dose adjustment 6. However, your situation differs: you have a rising INR despite holding doses, suggesting either:
- Dietary changes reducing vitamin K intake
- New drug interactions
- Intercurrent illness affecting warfarin metabolism
Research supports "watchful waiting" for slightly out-of-range INRs (3.01-3.49), showing this approach is safe with no major bleeding events during 14-30 day follow-up 1, 7, 8. One study of 231 patients with INRs of 3.2-3.4 found only one epistaxis case (in 103 patients) when doses were maintained 8.
When to Resume Warfarin
Once INR falls to 2.5-3.0, restart at a reduced dose. Most dose adjustments should alter the total weekly dose by 5-20% 4. For example, if you were taking 35 mg/week (5 mg daily), reduce to approximately 30-33 mg/week.
Red Flags Requiring Immediate Attention
Seek emergency care if you develop:
- Any bleeding (nosebleeds, blood in urine/stool, unusual bruising)
- Severe headache
- Abdominal pain
- Falls or trauma
The FDA label emphasizes that bleeding risk increases significantly with INR >4.0 3, though your current 3.9 represents moderate elevation without active bleeding.
Common Pitfall to Avoid
Do not make excessive dose reductions (>20%) for mildly elevated INRs, as this can cause the INR to drop too low, increasing thrombotic risk 8. The goal is gradual adjustment, not overcorrection.